Saw this post this morning. For those of us with HRD (BRCA,etc..), this may have clinical implications: Should the treatment be brought forward? And would it be more effective for this cohort? There are some small-sample studies that collaborate on both accounts. Far from a proof, but I think that's definitely worth discussing with MOs.
"TAKE-HOME MESSAGE
In this retrospective study, expression of membranous prostate-specific membrane antigen (PSMA) was scored via immunohistochemistry and was correlated with sequencing (matching same-patient biopsies) and clinical data. The expression of membranous PSMA was heterogeneous, more common in castration-resistant disease, and associated with a higher Gleason score (P=.04), and worse overall survival (P=.006). In addition, tumors with DNA damage repair had more membranous PSMA expression (P=.016), specifically aberrations in BRCA2 and ATM in the validation cohorts.
As PSMA theranostics is gaining increasing interest as a valid treatment option for metastatic prostate cancer, this very interesting and provocative study raises important questions regarding the expression of PSMA and genomic markers of response, deserving further investigation."
Oligometastatic prostate cancer: Metastases-directed therapy?
\"Bombesin - A New Frontier for Prostate Cancer Imaging\"
If insurance denies PSMA PET coverage for an approved use, appeal!
Stage 4 A Prostate cancer
